We're catalyzing discoveries that prevent, detect, and cure disease - Disruptive Companies from Great Science
| Full firm name | ARCH Venture Partners |
| Investment thesis/focus | We're catalyzing discoveries that prevent, detect, and cure disease - Disruptive Companies from Great Science |
| Headquarters and offices | Chicago, IL and Seattle, WA |
| Year founded | 1986 |
| Number of team members | Approximately 20+ team members (22 listed on CB Insights) |
| Founding/Co-founding partners | Robert Nelsen, Keith Crandell, Clinton Bybee (Co-founder & Managing Director, Emeritus) |
| Investment stage and check size | $50K to as much as hundreds of millions of dollars, per company |
| Business registration | Registered Illinois business entity |
| Office addresses | Chicago: 200 E Randolph St, Suite 2400, Chicago, IL 60601 | Seattle: 1201 Third Avenue, Suite 2550, Seattle, WA 98101 | Phone: (312) 606-0030 |
| Notable past and current portfolio companies | Illumina, Alnylam, Juno Therapeutics, Receptos, Agios, Bluebird Bio, Resilience, Codiak Bio, Denali Therapeutics, GRAIL, KARA TX, Beam TX, Lyell Biotech, Vir Bio, Sana, Homology Medicines, Gossamer Bio, Decode, ScholarRock, Unity Biotechnology, Vividion, Carrick Therapeutics, Boundless Bio, Thermo Fisher, PerkinElmer, Mallinckrodt, Hua Medicine, Quanterix, Syros, Twist Bioscience, Ultivue, Array Biopharma |